| DATE | TITLE | PDF |
| 03/06/07 | Leading Pharmaceutical Firms Support National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO) System Will Detect Substance Abuse PatternsLeading Pharmaceutical Firms Support National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO) System Will Detect Substance Abuse Patterns Newton, MA, -- Inflexxion, Inc., producers of scientifically validated and cost-effective interactive technology solutions for critical areas of health care, today announced that Endo Pharmaceuticals and Alpharma, Inc. have become founding sponsors of its National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO). With additional support from the National Institute on Drug Abuse (NIDA), Inflexxion has designed NAVIPPRO to be a real-time national monitoring system for detection of prescription opioid drug abuse. Using data from substance abuse treatment centers across the country, the NAVIPPRO system will detect changes in prescription opioid drug abuse patterns and estimate relative rates of abuse based on careful statistical methodologies. |  |
| 07/02/07 | ASI-MV® Connect Takes Addiction Assessment To The Next LevelASI-MV® Connect Takes Addiction Assessment To The Next Level Inflexxion Inc., today announced the launch of the Addiction Severity Index-Multimedia Version® Connect program, a powerful, new substance abuse assessment system. The ASI-MV Connect is the web-enabled version of the ASI-MV and consists of three major components: the client self-administered ASI-MV interview; tailored reports populated with client-specific data; and a powerful data analysis tool, the ASI-MV Connect Data Center. | |
| 06/04/08 | NAVIPPRO™ Presents at the Food and Drug AdministrationNAVIPPRO™ Presents at the Food and Drug Administration On June 4, 2008, the Inflexxion team presented the National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO) to an audience of approximately 100 as part of the Scientific Rounds at the Food and Drug Administration in Rockville, Maryland. Stephen F. Butler, PhD, Chief Science Officer at Inflexxion, and John Brownstein, PhD, NAVIPPRO Senior Consulting Advisor, led the presentation. | |
| 09/22/08 | Kaiser Permanente Recommends Brief Screening Tool to Mitigate Risk of Opioid AbuseKaiser Permanente Recommends Brief Screening Tool to Mitigate Risk of Opioid Abuse Kaiser Permanente’s National Pain Management Advisory Group today announced its first recommended practice tool, the Screener and Opioid Assessment for Patients in Pain (SOAPP®). This tool was developed by Inflexxion, Inc., of Newton, MA and is recommended by Kaiser Permanente to assist primary care physicians in improving pain treatment. The Kaiser Permanente network covers eight regions, including 13,000 physicians at 320 hospitals and reaches nearly nine million members nationwide. | |
| 02/23/09 | New publication describes program for monitoring prescription drug abuse, managing riskNew publication describes program for monitoring prescription drug abuse, managing risk Inflexxion is pleased to announce the publication of a study evaluating a core component of the National Addictions Vigilance Intervention and Prevention Program (NAVIPPROTM ). NAVIPPRO is a comprehensive risk management program for post-marketing surveillance of Schedule II and III medications. The program monitors, on an active, ongoing basis, indicators of adverse drug events, such as an emerging trend of abuse. | |